GleamWall
中文EN

GENB Generate Biomedicines, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2100782 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets26.1%
Debt / equity0.00x
Current ratio5.01x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue$4.22M$6.31M$7.22M$9.63M$10.13M$8.82M
R&D expense$82.25M$64.33M$57.81M$62.15M$59.73M$46.83M
SG&A expense$13.47M$13.60M$13.52M$10.29M$10.54M$10.15M
Operating income-$91.51M-$71.61M-$64.11M-$62.81M-$60.15M-$48.15M
Interest expense$192,000$155,000$182,000$253,000$307,000$368,000
Pretax income-$87.61M-$67.20M-$61.69M-$60.00M-$56.70M-$44.26M
Income tax$49,000$53,000$28,000$34,000$44,000$56,000
Net income-$87.66M-$67.25M-$61.45M-$53.62M-$52.43M-$41.69M
EBITDA-$87.81M-$68.41M-$60.84M-$59.51M-$56.85M-$44.74M
EPS (basic)-0.68-0.52-1.07-1.97-1.94-1.62
EPS (diluted)-0.68-0.52-1.07-1.97-1.94-1.62
Weighted avg. shares (diluted)128.51M128.24M64.87M33.04M33.00M32.79M
Balance sheet
Cash & equivalents$140.35M$135.36M$160.57M$118.52M$154.26M$220.61M
Short-term investments$263.86M$322.06M$356.07M———
Current assets$414.64M$470.25M$535.39M———
PP&E, net$38.65M$27.30M$27.84M———
Total assets$515.89M$561.69M$625.74M———
Current liabilities$82.72M$56.64M$58.39M———
Total liabilities$134.73M$105.64M$110.94M———
Shareholders' equity$381.16M$456.05M$514.80M-$566.44M-$517.85M-$471.00M
Shares outstanding129.02M128.27M128.19M———
Cash flow statement
Operating cash flow-$54.86M-$57.94M-$80.39M-$48.43M-$48.75M-$53.18M
Capital expenditure$2.15M$933,000$3.78M$235,000$154,000$751,000
Free cash flow-$57.01M-$58.88M-$84.17M-$48.66M-$48.91M-$53.93M
Investing cash flow$56.36M$33.31M-$259.93M$9.18M-$17.07M$75.53M
Financing cash flow$3.49M-$579,000$378.89M$3.79M-$263,000$20.56M
Depreciation & amortization$3.70M$3.20M$3.27M$3.30M$3.30M$3.41M
Stock-based compensation$8.06M$8.24M$6.39M$4.82M$5.49M$4.74M

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.